Commentary · 21 Feb 2026
Conference abstractPublished 26 Jun 2017
Cancer stem cells in isocitrate dehydrogenase wild type glioblastoma express components of the reninangiotensin system and cathepsins B, D and G
Gillies McIndoe Research Institute, Wellington, New Zealand Wellington Regional Hospital, New Zealand Hutt Hospital, New Zealand
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction: Isocitrate dehydrogenase wildtype glioblastoma (GB), the most aggressive form of brain glioma, is associated with a median survival of 25 months. Cancer stem cells (CSCs) have been proposed to be the origin of many cancers, including GB. Reninangiotensin system (RAS) has been associated in CSCs in different types of cancers. This study aimed at identifying and characterising the CSC population within GB tissues for the CSC markers, components of the RAS, and the protease cathepsins B (CathB), D (CathD) and G (CathG), which provide potential bypass loops for the RAS. As well neuro-spheres derived from fresh GB samples were investigated their expression of stem cell markers, TRA 1-60, OCT4, SOX2 and SSEA-1, and the aforementioned markers. Methodology: DAB and immunoflourenscent immunohistochemical (IHC) staining was performed on 7 GB samples for the expression of CSC markers SALL4, OCT4, SOX2, pSTAT3 and NANOG; components of the RAS, namely pro-renin receptor (PRR), angiotensin converting enzyme (ACE), angiotensin II receptor 1 (ATIIR1) and angiotensin II receptor 2 (ATIIR2); and CathB, CathD and CathG. NanoString mRNA analysis was performed on 5 of the original 7 GB samples, for the transcriptional expression of the same markers. 6 fresh samples of the original cohort of GB were grown in culture and stained for TRA 1-60, OCT4, SSEA-1 and SOX2, markers associated with CSCs. These cells were subjected to transcriptional analysis for CSC makers, components of RAS and CathB, CathD and CathG. Results: IHC staining demonstrated a significant number of GB cells expressing SOX2 and pSTAT3. A subset of these expressed OCT4, SALL4 and NANOG. NanoString mRNA analysis demonstrated the expression of mRNA transcripts for the markers examined. Cultures of GB tissues yielded tumour-spheres which expressed TRA 1-60, OCT4, SSEA-1 and SOX2. These tumour-spheres also expressed mRNA transcripts for the CSC and RAS markers, CathB and CathD demonstrated by IHC staining on GB tissues. Conclusion: The finding of this study confirms the putative presence of 2 CSCs within GB. The ability for primary cells derived from GB to form tumour-spheres in vitro, that express CSCs markers underscores the critical role of CSCs in the biology of GB. The expression of the components of the RAS, CathB and CathD, but not CathG by CSCs in GB and the GB-derived tumour-spheres, suggests CSCs as a novel therapeutic target by modulation of the RAS using existing medications.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Cancer Science & Therapy.
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Tinte Itinteang”
- BylineArticles whose byline prints “Agadha Wickremesekera”
- BylineArticles whose byline prints “Helen D Brasch”
- BylineArticles whose byline prints “Matthew J Munro”
- BylineArticles whose byline prints “Paul F Davis”
- BylineArticles whose byline prints “Swee T Tan”
